Contribution of the factors to EuroQol 5 Dimensions in rheumatoid arthritis patients achieving low disease activity/remission with abatacept treatment: post-hoc subgroup analyses of the Japanese real-world observational "ORIGAMI" study

Masayoshi Harigai; Eiichi Tanaka; Eisuke Inoue; Naoto Tamura; Kenta Misaki; Takanori Azuma; Shintaro Hirata; Fuminori Hirano; Yoshinori Taniguchi; Masaki Mitsuhashi; Masahiro Kondo; Motohiro Oribe; Kazutoshi Aoki; Michiaki Kadode; Katsuki Tsuritani; Hisashi Yamanaka

doi:10.1093/mr/road082

Contribution of the factors to EuroQol 5 Dimensions in rheumatoid arthritis patients achieving low disease activity/remission with abatacept treatment: post-hoc subgroup analyses of the Japanese real-world observational "ORIGAMI" study

Mod Rheumatol. 2023 Aug 25:road082. doi: 10.1093/mr/road082. Online ahead of print.

Authors

Masayoshi Harigai¹, Eiichi Tanaka¹, Eisuke Inoue^{1

2}, Naoto Tamura³, Kenta Misaki⁴, Takanori Azuma⁵, Shintaro Hirata⁶, Fuminori Hirano⁷, Yoshinori Taniguchi⁸, Masaki Mitsuhashi⁹, Masahiro Kondo¹⁰, Motohiro Oribe¹¹, Kazutoshi Aoki¹², Michiaki Kadode¹³, Katsuki Tsuritani¹⁴, Hisashi Yamanaka^{1

15}

Affiliations

¹ Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
² Showa University Research Administration Center, Showa University, Tokyo, Japan.
³ Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.
⁴ Department of Rheumatology, Kita-Harima Medical Center, Hyogo, Japan.
⁵ Azuma Rheumatology Clinic, Saitama, Japan.
⁶ Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.
⁷ Department of Rheumatology, NHO Asahikawa Medical Center, Hokkaido, Japan.
⁸ Department of Rheumatology, Bayside Misato Medical Center, Kochi, Japan.
⁹ Department of Nephrology, Yokohama Minami Kyousai Hospital, Kanagawa, Japan.
¹⁰ Department of Rheumatology, Shimane University Hospital, Shimane, Japan.
¹¹ Department of Rheumatology, Oribe Rheumachika Naika Clinic, Oita, Japan.
¹² Aoki Medical Clinic, Saitama, Japan.
¹³ Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
¹⁴ Department of Immunology Medical, Bristol Myers Squibb K.K., Tokyo, Japan.
¹⁵ °Department of Rheumatology, Sanno Medical Center, Tokyo, Japan.

PMID: 37624029
DOI: 10.1093/mr/road082

Abstract

Objectives: To address improvements in quality of life (QOL), we analysed the relative contributions of factors to EuroQol 5 Dimensions (EQ-5D) in abatacept-treated rheumatoid arthritis (RA) patients in the ORIGAMI study.

Methods: Patients who were evaluable for disease activity through to Week 52 in the ORIGAMI study were divided into those achieving Simplified Disease Activity Index-remission/low disease activity (remission/LDA; n=178) and patients with moderate/high disease activity (MDA/HDA; n=99). We compared the changes in EQ-5D and other outcomes through to Week 52. Focusing on the remission/LDA group, the contribution of each factor to the variance of EQ-5D at baseline and Week 52 was examined using analysis of variance.

Results: The remission/LDA group showed greater improvements than the MDA/HDA group in EQ-5D, Japanese Health Assessment Questionnaire, visual analogue scale for pain (Pain VAS), and patient global assessment (PtGA). In the remission/LDA group, factors significantly contributing to EQ-5D were sex, C-reactive protein, and Pain VAS at baseline, and PtGA and age at Week 52.

Conclusions: In RA patients who achieved remission/LDA during abatacept treatment, PtGA and age at Week 52 contribute to the variance of EQ-5D, suggesting that identification of factors associated with PtGA may be important to address improvements of QOL.

Keywords: abatacept; pain; patient’s global assessment; quality of life; remission; rheumatoid arthritis.